Information for Authors - Neurology.org
Browse by Topic
Journal Information
Neurology Resources
User Resources
Neurology(R) Neuroimmunology & Neuroinflammation
An Official Journal of the American Academy of Neurology
January 13, 2014
The mission of Neurology(R) Neuroimmunology & Neuroinflammation is to provide neurologists with peer-reviewed articles, editorials,
and reviews to enhance patient care, education, and clinical & translational research. Our vision is to be the premier peer-reviewed
journal for experts in the fields of Neuroimmunology and Neuroinflammation. We publish open-access reports of original research
and in-depth reviews of topics in multiple sclerosis, NMO, Guillain-Barré, myasthenia and inflamm related
reports focused on nervous system infection will also be featured.
Neurology: Neuroimmunology & Neuroinflammation is published six times per year. It is an online only, open-access journal.
** Please submit manuscripts at . Papers submitted to Neurology(R) Neuroimmunology & Neuroinflammation undergo the same thorough peer-review process as Neurology
submissions.
Authorship and Contributorship
Authorship Definition
Neurology: Neuroimmunology & Neuroinflammation defines an author as a person who has made a substantive intellectual contribution
to the submitted manuscript. A substantive contribution includes one or more of the following:
o Design or conceptualization of the study
o OR analysis or interpretation of the data
o OR drafting or revising the manuscript for intellectual content
Professional writers employed by pharmaceutical companies or other academic, governmental, or commercial entities who have
drafted or revised the intellectual content of the paper must be included as authors.
It is the responsibility of the authors of a manuscript to designate the corresponding author, determine author order, and
decide which persons in the study are authors and which are contributors according to the journal’s criteria. Please note
that the author list/author order MUST be finalized prior to first submission. Author addition, omission, or change in author
order will require additional documentation. See
Authorship Requirements
o Manuscripts submitted for publication must list all Authors, including the person who drafted the original manuscript.
The Journal considers ghostwriting (undisclosed authorship) all authorship needs to be disclosed.
o All those qualifying for authorship must give final approval of the version to be published and take responsibility for
the conduct of the research.
o All those qualifying for authorship must indicate their contributions to the article on the Authorship Agreement form.
o One author, the Principal Investigator or Guarantor, must have access to all the data and take responsibility for the
data, accuracy of the data analysis, and the conduct of the research.
o One author, the Corresponding Author, must be responsible for all communications with the Journal throughout the review
process, including ensuring that all Authors have approved the final submitted version, revised versions before they are submitted,
and the final accepted version of the manuscript. The Corresponding Author is responsible for uploading all submissions and
co-authors are not permitted to perform this function within the system. The Corresponding
Author is also responsible for determining which members in a study attributed to a Group meet criteria for authorship. The
Corresponding Author also takes responsibility for listing Coinvestigators (who do not qualify for authorship) in a "Coinvestigators"
data supplement and Contributors (who do not qualify for authorship) in a Contributors appendix or in the Acknowledgment Section
with their roles and contributions in parentheses. When the study represents the work of a study group, use "on behalf of";
or "for"before the name of the study group in the byline unless all members of the group have qualified for authorship as
stated above.
o All Authors must complete the , , and the
forms if the submitted manuscript is invited for revision after peer review. If the Author's employer is the federal government,
the Author must indicate this in the appropriate place on the Publication Agreement Form. It is critical that the Corresponding
Author include all other authors' correct email addresses in t doing so will prevent delays in notifications
to authors to complete required forms at the appropriate times.
o Multi-center trials attributed to corporate or multiple authors of a Study Group must list all Authors qualifying according
to the criteria above in the author byline OR in an &Additional Authors& Appendix along with their disclosure information.
o If the bylined Author list is longer than the Author column on the first page of the published article will accommodate,
the authors whose names do not fit will be listed in the &Additional Authors& Appendix. A listing of author disclosures
that do not fit in the Disclosure footnote on the first page of the published article will also be included in a Disclaimer
section at the end of the article.
o Acting as a Coinvestigator or study coordinator for a multi-center study does not constitute authorship. Contributions
such as supporting the study, contributing materials or participants, general supervision of study personnel, technical assistance,
or collecting data do not constitute authorship.
o "Guest" or "honorary" authorship based solely on position (e.g., research supervisor, department head) is not permitted.
Coinvestigators (Non-Authors) and Contributors (Non-Authors)
Neurology: Neuroimmunology & Neuroinflammation defines a Coinvestigator as a person who does not meet the criteria for authorship
of a study, but who acted as a coinvestigator or study coordinator for a multi-center trial. Neurology: Neuroimmunology &
Neuroinflammation defines a Contributor as a person who does not meet the criteria for authorship of the study, but who has
contributed in other ways, such a
contribution of drugs, reagents, equipment, or editing the manuscript for non-intellectual content.
o Coinvestigators for multi-center trials who do not meet the criteria for Authorship must be listed in a "Coinvestigator"
data supplement that includes each person's affiliation and role. This Coinvestigator supplement must be uploaded as a Supplement
o Contributors who do not meet the criteria for Authorship must be listed in a Contributors supplement that includes each
person's affiliation and contributions. This supplement must be uploaded as a Supplemental File.
oIf individuals in a study group qualify as authors, note these requirements:
o Each individual in the group who qualifies as an author must be listed in the author field at submission.
o Each individual in the group who qualifies as an author must complete authorship, disclosure, and publishing agreement
forms if the manuscript is accepted.
o The corresponding author must send an email message to Kathy Pieper, Managing Editor of Neurology, (), confirming if any study group members qualify as authors so that Neurology: Neuroimmunology & Neuroinflammation can ensure
correct editorial and post-production processes are followed.
o Neurology: Neuroimmunology & Neuroinflammation will not publish links to Web sites listing Coinvestigators or Contributors.
The Corresponding Author must supply the information formatted as below and include name, degree(s), and, in parentheses,
location and role:
o COINVESTIGATORS
o Janet Worth, MD, PhD (Mayo Clinic Jacksonville, Director of Coordinating Center); John Thoreson, MD (Cleveland Clinic,
Core PI of MRI Committee); Edward Blank, MD, PhD (UCLA, Site Investigator); Lauren Pickett, MD, PhD (Columbia University,
Site Investigator); Abraham Monte, MS, PhD (UCLA, Publication Committee); and Abert Reitz, MD, PhD (Tulane, Chair, Advisory
Committee).
o Disclosures for Coinvestigators and Contributors are not published. Although Coinvestigators and Contributors are not
required to submit disclosures, the Corresponding Author should be aware of any disclosures that they may have.
o Unless all authors of a study group qualify as authors, do not list the study group
the byline may
read “for” or “on behalf of” the study group.
For a table outlining the responsibilities of Corresponding Authors, Principal Investigators, Authors, Coinvestigators,
and Contributors, .
Acknowledgments
The Acknowledgment section allows authors space to recognize and express appreciation to others (Contributors) who have
contributed to the study but have not qualified as Authors or Coinvestigators. In this section, list those who have collected
contributed drugs, reagents, equipment,
or edited the manuscript for non-intellectual content. The list must include the contributors' affiliations and the specific
contributions made by each. The Acknowledgment section is also reserved for authors to thank individuals who have provided
general advice or guidance, review of the manuscript, and technical help. For those helping in preparation of the manuscript,
specify how they assisted (e.g., performed substantive or technical editing, copyedited the manuscript, prepared tables or
figures, or provided clerical assistance).
Changes in Authorship after Submission
The corresponding author must alert and provide an explanation to the editorial office if there is any change in authorship
status (addition, omission, or author order) after manuscript submission. The corresponding author must request and gather
letters of agreement from all authors of the manuscript including the author who is being added or omitted. At revision, these
statements can be uploaded as Additional files in the online system. See .
Conflict of Interest and Disclosure
Neurology: Neuroimmunology & Neuroinflammation complies with the position of the International Committee of Medical Journal
Editors on "Conflict of Interest". Conflict of interest for authors is defined as "financial and other conflicts of interest
that might bias their work." In addition, Neurology: Neuroimmunology & Neuroinflammation has adopted the Conflict of Interest
and Disclosure Policy of the American Academy of Neurology. This policy requires complete disclosure from all authors of all
financial relationships or other competing interests that could be perceived as biasing the study whether or not this support
was related to the subject of the manuscript. All authors' financial relationships (and those of their "immediate family members")
from the past two years must be disclosed regardless of whether these relationships are related to the study described in
the submitted manuscript. If the study period of the submitted manuscript exceeded two years, financial relationships relevant
to the topic must also be disclosed.
Authorship, Disclosure, and Publication Agreements
All those qualifying for authorship are required to submit , , and
forms after the revision has been submitted. Each author will receive email notification and directions for accessing and
completing the forms on the Web site at the appropriate time. The Corresponding Author is responsible for ensuring that all
authors complete these agreements. It is critical that the Corresponding Author include all other authors' correct email addresses
in t doing so will prevent delays in notifications to authors to complete required forms at the appropriate
times. Members of a Group who are Coinvestigators or Contributors and do not fulfill the authorship requirements above are
not required to fill out these agreements.
for a list of all items to be included when filling out the online disclosure forms. Authors will be notified at the appropriate
time to complete disclosure forms, which must include all financial relationships (and those of their immediate family members)
from the past two years regardless of whether these relationships are related to the study described in the submitted manuscript.
If the study period of the submitted manuscript exceeded two years, financial relationships relevant to the topic must also
be disclosed. Failure to reveal all pertinent information constitutes a fraudulent submission and may cause a published paper
to be retracted and the authors to be prohibited from further submission to Neurology: Neuroimmunology & Neuroinflammation.
Note that after an author has completed the disclosure form for a manuscript, the form is accessible from the Personal Information
area in the manuscript tracking system for updating at any time.
o ALL author disclosures will be listed in a paragraph in print and on the pdf.
o A footnote on Page 1 of each article will call attention to the disclosures at end of article. Page 1 footnote: “Funding
information and disclosures are provided at the end of the article.”
Full Data Access
Clear statements of industry-sponsored research and author participation in corporate activities are required for evaluation
of a manuscript. For industry-sponsored and all other research, Neurology: Neuroimmunology & Neuroinflammation Neurology now
requires the Principal Author or Guarantor to declare in the Authorship Agreement Form that they take full responsibility
for the data, the analyses and interpretation, and the con that they have full acces
and that they have the right to publish any and all data, separate and apart from the guidance of any sponsor. These statements
must be made in the cover letter.
Scientific Misconduct, Breach of Publication Ethics, and Embargo Policy
o Scientific misconduct includes fabrication, falsification, and plagiarism by the authors.
o Breaches of editorial policies include failure to reveal financial c omitting a deserving author
or adding a non- misrepresenting publication status in the Reference list (erroneously claiming that a
paper is "In Press"); self-plagiarism and duplicate or redundant publication.
o Redundant or duplicate publication is publication of data, tables, figures, or any other content that substantially overlaps
with other material published previously or to be published in the future. This includes work published by others or any author
of the manuscript submitted to Neurology: Neuroimmunology & Neuroinflammation . When submitting a paper, the author should
make a full statement to the Editor in the cover letter about all submissions and previous reports (in any language) that
might be regarded as redundant or duplicate publication of the same or very similar work. The author should alert the Editor
if the work includes subjects about which a previous report has been published or about a manuscript that is under review
by, submitted to, in press at, or to be submitted to or published in the future by another journal. Any such work should be
referred to and referenced in the new paper and a copy of the material should be included with the submission. Abstracts presented
at scientific meetings (with no press releases and not discussed in detail at a symposium) and data provided as required to
clinical trial registries are not considered pre-published material.
o Plagiarism is the use of others' ideas or words without properly crediting the source. If authors include one or more
sentences verbatim from another source, the original source must be cited and the sentence(s) put in quotation marks to avoid
plagiarism. Authors must not use materials of others (text, figures, images, tables) without permission and attribution, including
their own published work. See Miguel Roig, Avoiding plagiarism, self-plagiarism, and other questionable writing practices:
A guide to ethical writing (). Inadvertent duplication and intentional plagiarism have become more common in the digital age as cutting and pasting from
earlier articles an author has written or copying the works of another are easy to do. Neurology: Neuroimmunology & Neuroinflammation
has joined a number of other journals in using a software tool created by CrossRef to check for overlap in submitted manuscripts.
When Neurology: Neuroimmunology & Neuroinflammation receives a manuscript revision, a staff member will use the software to
compare it against published articles to see if overlap exists. We may ask for minor revisions if the software report indicates
minor amounts of recycled text, especially in the Methods and Introduction sections, so that we are not violating copyright
issues. Larger amounts of duplicated material may require obviously, manuscripts with excessive duplication
in the Results and Discussion sections will be rejected. (Wording adapted from Baskin PK & Gross RA, Neurology -4.)
o Embargo is the prohibition for copyright reasons from releasing findings in a submitted or accepted paper to the public
until after the article has been published Prior to publication, authors may not release information to the press and must
ensure that other organizations or institutions have been instructed of this policy. Exceptions to the embargo policy can
be made at the Editor's discretion for papers presented at the AAN Annual Meetings or in situations in which the article describes
major medical advances deemed critical to public health. Consequences resulting from violation of the embargo may include
retraction of the accepted paper or loss of privileges of publishing in the Journal in the future. Credentialed representatives
of the press may request further information about embargoed articles, including receiving advance copies of articles and
help coordinating interviews with researchers, by contacting the American Academy of Neurology Media and Public Relations
Department: Rachel Seroka, Associate Director of Media and Public Relations at . Post-embargo press releases
are available at .
o Editorial action will be expected in cases of scientific misconduct, breaches of publication ethics, and embargo violations.
Editorial actions that may be taken include publication of the breach in the Journal, retraction of published articles, notification
of institutional authorities, and loss of privileges of publishing in the Journal in the future.
Neurology: Neuroimmunology & Neuroinflammation has an Ombudsman. Appointed by the American Academy of Neurology Board of
Directors, this person acts as a mediator between authors and the Editorial Office. The Ombudsman can investigate editorial
process: delays in peer review, challenges to publication ethics, and cases of editorial bias. The Ombudsman will address
the editorial process and will not handle complaints about the substance of editorial decisions, criticisms regarding editorial
content, or accusations of scientific misconduct. The complainant should contact the Editorial Office first to resolve the
problem. If the complaint is not resolved by contacting the Editorial Office, the complainant may contact the Ombudsman, Lewis
P. Rowland, MD, Neurological Institute, 710 West 168th Street, Columbia University Medical Center, New York NY 10032, Phone:
212-305-8551, e-mail: .
Clinical Trial Guidelines
According to ClinicalTrials.gov, "clinical trials" are generally considered to be biomedical or health-related research
studies in human beings that follow a pre-defined protocol. ClinicalTrials.gov includes both interventional and observational
types of studies. Interventional studies are those in which the research subjects are assigned by the investigator to a treatment
or other intervention, and their outcomes are measured. Observational studies are those in which individuals are observed
and their outcomes are measured by the investigators.&
Statistics
Authors reporting clinical trials must indicate on the title page of the manuscript the specific author who carried out
the biostatistical analysis and the author's academic, governmental, or commercial affiliation.
Data resulting from a non-clinical trial should be cited with mean +/- Standard Deviation or Standard Error (with SD or
SE indicated in the text or a table). If a P value is cited, the authors should indicate the statistic (e.g., 2-tailed T test,
Chi square test, Fisher test).
In the Results section of the manuscript, the following evidence-based medicine statistics must be included for the manuscript
to be forwarded for editorial review:
o Confidence
o Numbers needed to treat
o Absolute risk reduction
Standard Protocol Approvals, Registrations, and Patient Consents
In reporting experiments on human subjects, the authors must indicate in the cover letter and in the Methods that the procedures
were approved by an ethical standards committee on human experimentation (institutional or regional). Authors must comply
with the guidelines of the International Committee of Medical Journal Editors () with regard to patient consent for research or participation in a study. Do not use study participants' names, initials,
or hospital numbers anywhere in the manuscript (including figures).
In addition to the standard patient consent for participation in research, authors are responsible for obtaining patient
consent-to-disclose forms for all recognizable participants in photographs, videos, or other information that may be published
in the Journal, in derivative works by the AAN, or on the Journal’s Web site. The consent-to-disclose form should indicate
specific use (publication in the medical literature, with the understanding that participants and the public will have access)
of the participant’s information and any images in figures or videos and must contain the participant’s signature or that
of a legal guardian. The original should be retained by the guarantor or corresponding author. The consent-to-disclose form
accessed from this link is recommended.
Authors must comply with the guidelines of the International Committee of Medical Journal Editors () with regard to experiments on animals. Authors must indicate in the cover letter and the Methods that the procedures comply
with the institutional and national guide for the care and use of laboratory animals.
Reporting Guidelines
o Randomized Controlled Trials. Authors reporting the results of Phase 1, Phase 2, or Phase 3 randomized controlled trials
must submit a CONSORT checklist and flow diagram available at: . Authors must also provide a flow diagram as Figure 1 of the submitted manuscript. Authors of uncontrolled, pilot trials
are not required to complete the CONSORT checklist or flow diagram.
o Systematic Review or Meta-analysis. Authors reporting systematic review or meta-analysis of randomized trials must submit
the PRISMA (previously named QUOROM) statement, which is available at: .
o Diagnostic Accuracy. Authors reporting studies of the accuracy of diagnostic tests should provide the completed STARD
checklist. Authors must also provide a flow diagram as Figure 1 of the submitted manuscript. The STARD checklist is available
o Observational Studies. Neurology: Neuroimmunology & Neuroinflammation requires the STROBE checklists for cohort, case-controlled,
and cross-sectional studies and all observational studies of human subjects as well as case series, pilot studies, genetic
linkage studies, and retrospective data collection studies. If the detailed methods are explicitly stated in the manuscript
for single case studies, STROBE is not needed. Please make note on this checklist () which page numbers of the manuscript include the requested information.
o Genetic Association Studies. Authors reporting genetic association studies must submit the STREGA checklist available
o Reporting Adverse Events. In case reports, authors should state whether they have reported serious adverse events to the
manufacturer, US FDA, or other governmental regulatory agency.
Checklists can be uploaded as Supplemental/Additional Files or faxed to (612) 454-2748.
Registration of Clinical Trials
Neurology: Neuroimmunology & Neuroinflammation requires investigators to register their clinical trials in a public trials
registry and to provide the identification of the clinical trial registry and the clinical trial identification number. The
National Library of Medicine provides a free registry () that meets the International Committee of Medical Journal Editors (ICMJE) requirements. Investigators are required to register
at or prior to patient enrollment. This policy has been effective for any clinical trial beginning enrollment after July 1,
2005. Neurology: Neuroimmunology & Neuroinflammation will not consider for publication trials that are retrospectively registered.
For further information on definitions and other considerations, access
Section III.J. Authors must provide the clinical trial identifier number in the Methods section of the submitted article.
The Food and Drug Administration Amendment Acts of 2007 require mandatory results reporting for clinical trials. (See .)
Neurology: Neuroimmunology & Neuroinflammation , following the ICMJE policy, will not consider results posted in the same
clinical trials registry that contains the primary registration as being previously published if the results are presented
in the form of a brief, structured (≤500 words) abstract or table. The authors should alert the editor in the Cover Letter
at submission that review of the manuscript should be accelerated if possible.
Levels of Evidence
Authors submitting Articles to Neurology: Neuroimmunology & Neuroinflammation that report on clinical therapeutic intervention
studies (clinical trial or use of medication, procedure, maneuver, or change in patient environment intended to benefit the
patient) must state in the Abstract and Methods the primary research question(s) and the classification of assigned to each question based on the . Authors of Clinical/Scientific Notes that report on clinical therapeutic intervention studies must state the primary research
question and level of evidence at the end of the manuscript. Authors will initially assign a level of evidence. If the submission
is invited for revision, an independent team affiliated with the AAN guidelines committee will review, adjudicate, and assign
the level of evidence they deem as appropriate and related to the author with the reviewers' comments. If aspects of the manuscript
can be adjusted to raise the level of evidence assignment, the authors should indicate this in the Response to Reviewers when
returning the revision. The final level of evidence will be assigned by the guidelines committee before final publication.
For more information, access the following articles and the editorial on the use of classification of levels of evidence published
in Neurology:
1. French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology 4-1638.
2. Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should
care. Neurology 9-1643.
3. Gross RA, Johnston KC. Levels of evidence: taking Neurology to the next level. Neurology -10.
Permissions
Authors must submit written permission from the copyright owner (usually the publisher) to use direct quotations, tables,
or illustrations that have appeared in copyright form elsewhere, along with complete details about the source. Any permissions
fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material,
not the responsibility of Lippincott Williams & Wilkins
Because all Neurology: Neuroimmunology & Neuroinflammation articles are published open access, authors retain copyright.
Papers may be reproduced with permission from and attribution to the author, but not used for commercial use.
To request permission and/or rights to use content from Neurology: Neuroimmunology & Neuroinflammation for commercial use,
please go to the Journal Web site and click the "Request Permissions" tool to the left of the article. Alternatively, send
an e-mail to . The exception is that articles published according to the open access route by RCUK and Wellcome Trust authors
may be re-used for commercial purposes without request. Please see the FAQ for open access options.
Use of Generic and Proprietary Drugs and Devices
At first mention of a drug or device in a manuscript, authors must state the generic name with the proprietary name in parentheses
along with the name, city, and state of the manufacturer. In subsequent mentions, the generic name should be used. Clinical/Scientific
notes only need to list the generic name unless the paper compares two medications.
Genetic Studies
o Authors of genetic association studies must consider whether their results are likely to be considered of sufficient power
and interest to warrant publication. Neurology: Neuroimmunology & Neuroinflammation follows the guidelines outlined by authorities
in the genetics research field (Neurology 3-1154 and Nature Genetics 23). Calculations of statistical
significance must make appropriate corrections for multiple testing. After such correction, the (experiment-wise) significance
level must not exceed 0.01 and should preferably be smaller than that limit.
o For standard pedigree symbols and nomenclature, please refer to the established guidelines (Am J Hum Genet -52).
Authors should also follow the mutation nomenclature rules of the Human Genome Variation Society (). In addition, authors reporting such sequence variants of a gene should submit it to the gene-specific mutation database
before the manuscript is submitted to confirm its accuracy.
o Methodological information such as primer sequences or PCR conditions should be submitted with the main manuscript as
Supplemental Data for review purposes only.
o Hardy-Weinberg Equilibrium (HWE) values must be calculated and reported in population genetic studies submitted to Neurology:
Neuroimmunology & Neuroinflammation.
NIH-Funded Studies and Public Access
Lippincott, Williams & Wilkins (LWW), publisher of Neurology: Neuroimmunology & Neuroinflammation, will submit an electronic
version, on behalf of the authors, of final published articles to PMC within 6 months after publication. The authorization
is a non-exclusive license only for the purpose stated in the NIH Public Access Policy. Further information on the NIH Public
Access Policy is available at:http://publicaccess.nih.gov&/
See Funding Agency Policies.
Authors must acknowledge explicitly in the text of their research articles the funding source of the research and, if applicable,
their institutional affiliation with the appropriate agency. They must also check the appropriate funding box on the Publication
Agreement form.
Neurology: Neuroimmunology & Neuroinflammation is an open access, peer reviewed journal. To provide open access, the journal
charges publication fees for each article they publish. These fees cover the expenses incurred by publication, including the
peer review process, journal production and publication, and hosting and archiving fees. Fees vary by article type. Please
note there will not be a charge for invited Editorials.
Neurology: Neuroimmunology & Neuroinflammation’s follows the Gold OA model..” (Adapted from Baskin PK & Gross RA, Embracing
open access publishing: A new era for Neurology. Neurology 81 July 2, 2013)
o Gold OA (for authors not funded by RCUK and Wellcome Trust). Authors (including authors of commercially sponsored papers)
will have articles published in final form as OA. Authors must sign a license giving the publisher the right to publish the
article, create derivatives, and sell reprints. The authors retain the copyright and anyone can use the article for non-commercial
purposes with proper attribution to Neurology: Neuroimmunology & Neuroinflammation as the original publisher. Each author
will sign a license that will give him/her the rights outlined in the Creative Commons: Attribution-Non Commercial-No Derivatives
(CC BY-NC-ND) License. This license does not permit commercial exploitation or the creation of derivative works without specific
permission. Additonally, all authors will have their final published article deposited into PMC. The article processing charge(APC)
is $3200 per article in 2014. The charge for publication of Clinical/Scientific Notes and Editorials is $500
o Gold OA (for authors funded by RCUK and Wellcome Trust). Authors funded by RCUK and Wellcome Trust must sign a license
giving the publisher the right to publish the article. The authors retain copyright but anyone may reuse the article and create
derivatives, even for commercial purposes, with proper attribution to Neurology: Neuroimmunology & Neuroinflammation as the
original publisher. Authors will be required to publish, as per the RCUK mandate and Wellcome Trust policy, under the Creative
Commons: Attribution (CC-BY) License. Only RCUK and Wellcome Trust authors are allowed to choose this option and must pay
an APC of $3200 per article.
To ensure timely publication, authors should be prepared to submit article processing charge within 5 business days after
acceptance.
Credit card and “Bill Me” options are available for author, funding agency or institution. Access the payment
site at: /
With both the gold OA options, all authors will continue to sign
as these forms provide the mechanism for the publisher to ensure that the authors are fully compliant with the requirements.
The Publication Agreement Forms are signed by all authors at provisional acceptance. The Corresponding Author (on behalf of
all authors) will also sign a License to Publish. The authors will retain the copyright.
It is the responsibility of the Corresponding Author to inform the Neurology: Neuroimmunology & Neuroinflammation Editorial
Office and/or LWW that they have RCUK or Wellcome Trust funding. Neither the AAN nor LWW will be held responsible for retroactive
deposits to PMC if the author has not completed the proper forms.
Articles are full-length reports of original research. These include large-scale pivotal trials of new therapies (randomized
clinical trials). According to ClinicalTrials.gov, clinical trials "are generally considered to be biomedical or health-related
research studies in human beings that follow a pre-defined protocol. ClinicalTrials.gov includes both interventional and observational
types of studies. Interventional studies are those in which the research subjects are assigned by the investigator to a treatment
or other intervention, and their outcomes are measured. Observational studies are those in which individuals are observed
and their outcomes are measured by the investigators." Specifications:
o Maximum of 3000 words (not including abstract, figure legends, table legends, references) and 6 tables.This length equals
about 15 double-spaced manuscript pages. If there are only 5 tables or figures, a word count of 3500 will be permitted.
o Structured Abstract containing Objectives, Methods, Results, and Conclusions, maximum 250 words.
o Limit of 40 references. The best references should be included rather than duplicative citations for single points. Citations
to non-peer-reviewed work should be avoided. If additional references are deemed important, they can be published online as
supplemental data. Review articles may have up to 60 references.
o Limit of 5 figures and tables total with a word count of 3500 words. 6 figures and tables will be permitted with a word
count of 3000 words. Tables should not repeat data in the text. Tables must be two double-spaced pages or less.
o Figure legends must explain what is represented in the figure rather than repeating results, methods, and conclusions.
Articles (Smaller Scope Studies)
Neurology: Neuroimmunology & Neuroinflammation will consider smaller (e.g., 10-50 participants), uncontrolled, nonrandomized,
or unblinded clinical trials as Articles. This category includes preliminary observations or pilot studies or presentation
of one or a few informative cases. These manuscripts should be uploaded under "Article" in the Neurology: Neuroimmunology
& Neuroinflammation tracking system. Editors will make final decisions regarding length of these articles. Specifications:
o Maximum of 1250 words (not including abstract, figure legends, table legends, references)
o Structured abstract, maximum of 250 words
o No more than 10 references
o Maximum of 3 tables or figures
Clinical/Scientific Notes
Clinical/Scientific Notes are abbreviated reports on cases or preliminary studies. Specifications:
o Maximum of 750 words
o No abstract (the title serves as abstract)
o No more than 1 table or figure
o No more than 7 references
The goal of this section is to encourage concise, rapid debate among authors and readers of Neurology: Neuroimmunology &
Neuroinflammation Letters are restricted to comments about studies published in Neurology: Neuroimmunology & Neuroinflammation
within the past two issues, with the exception of submissions identifying possible errors in data or data analysis or by appeal
to the Editor. The letters will be edited for clarity and length. Readers wishing to submit a letter should access the Letters
tab on the home page at
and follow instructions. Alternatively, interested submitters can access the online version of the article and click on "Letters:
Submit a Response" in the box on the right-hand side of the opening page. Letters are not indexed by PubMed.
Authors of letters sent to Neurology: Neuroimmunology & Neuroinflammation should keep the following statement from the Uniform
Requirements for Medical Journal Editors in mind:
"Although editors have the prerogative to sift out correspondence material that is irrelevant, uninteresting, or lacking
in cogency, they have a responsibility to allow a range of opinion to be expressed. The correspondence column should not be
used merely to promote the Journal's or the editors' point of view. In all instances, editors must make an effort to screen
out discourteous, inaccurate, or libelous statements, and should not allow ad hominem arguments intended to discredit opinions
or findings."
Specifications:
o Maximum of 200 words
o Maximum of 5 reference 1 must be the article on which you are commenting
o Maximum of 5 authors
Special Categories
Views & Reviews
Views & Reviews are either a review or an opinion statement that provides a summary of the most important recent information
on a topic. If the Review summarizes recommendations for practice, use the word "Recommendations" in the title rather than
"Guidelines." (Guidelines published in the Journal are created by an established process by the American Academy of Neurology.)
Specifications:
o Maximum of 3500 words, excluding references
o Abstract (structured optional), maximum 250 words
o Maximum of 60 references (additional may be added as online supplementary material). They should cite the most important
papers in the field. Neurology: Neuroimmunology & Neuroinflammation welcomes inquiries on Views & Reviews content or format
and will consider manuscripts proposing a Hypothesis only if written by an acknowledged contributor to the field.
o No more than 6 tables and/or figures
Rejected Manuscript Policy
The Editors of Neurology: Neuroimmunology & Neuroinflammation do not consider previously rejected manuscripts.
Required Forms
o : Authors will be prompted to complete these after a revision is submitted. Click
to see an example of an Author Agreement Form.
o : Authors will be notified of the address to access this online form after publication revision is submitted. It is critical
that the Corresponding Author include all other authors' correct email addresses in t doing so will prevent
delays in notifications to authors to complete required forms at the appropriate times. Click here to see an example of an
Author Disclosure F click here to see the list of items needed to fill out the form.
o : All authors must sign a Publication Agreement form if an article is to be accepted for publication and will be prompted
to complete this form online at the time a revision is requested. Researchers should review the contracts with their institutions
or funding groups to determine whether works created during the study are considered to be prepared as part of their duties
or not part of their duties as an employee. Forms for the following guidelines if applicable:
: Applicable only for authors reporting the results of Phase 1, Phase 2, or Phase 3 randomized controlled trials
: Applicable only for authors reporting systematic review or meta-analysis of randomized trials. This statement was previously
named QUOROM.
: Applicable only for authors reporting diagnostic accuracy.
: Applicable only for authors reporting case-controlled, cohort, and cross-sectional observational studies and all observational
studies of human subjects as well as case series, pilot studies, genetic linkage studies, and retrospective data collection
studies. Authors should fill out the portions that apply to their studies.
o . Applicable for authors reporting genetic association studies.
o License-to-Publish form if open access route is chosen by authors.
Please indicate the assigned manuscript number on all submitted forms. This number is provided to the corresponding author
at the conclusion of uploading the manuscript and in the e-mail verification of a successfully uploaded manuscript.
Manuscript Submission Guidelines
Author's Checklist
To submit a manuscript, go to http://submit.nn.neurology.org.
For a convenient Author's Checklist of important items to include in the manuscript, click . We recommend reading all the guidelines below before submitting a manuscript.
General Formatting
Manuscript submissions to Neurology: Neuroimmunology & Neuroinflammation should be prepared electronically and submitted
in a standard wo Microsoft Word is preferred. Although conversions can be made from other word processing
formats and PDF files, the vagaries of the conversion process may introduce errors. Do not submit ASCII text files. The manuscript
should be formatted so as to print out double-spaced at standard 8" x 11" or A4 (international) paper dimensions, using a
12-point font size and a default typeface (e.g., recommended fonts are Times, Times New Roman, Courier, Helvetica, and Arial).
Set the left margin at one inch, and the right margin at one-half inch or more. Do not just leave it
unaligned.
Place the page number and lead author's last name in the upper right-hand corner of each page (including the reference pages,
tables, and figure legends).
Observe the following guidelines in preparing your electronic manuscript file:
o Use hard returns only at the end of paragraphs and display lines (e.g., titles, subheadings)
o Do not insert a tab, indent, or extra spaces before the beginning of a paragraph or for list entries
o Do not indent run-over lines in references o Set line spacing at 2 (not 1.5 or 2.5)
o Optional: Number lines in manuscript
o Turn off automatic hyphenation and justification
o Do not use automatic references
o Do not insert hard page breaks
o Take care to enter "one" (1) and lowercase "el" (l), as well as "zero" (0) and capital "oh" (O), correctly
o Key dashes as follows: Use a single hyphen with space before it for a minus sign, and a double hyphen (with space before
and after) to indicate an em-dash (long dash) in text. Use only single hyphens in the references.
o Nonstandard characters (Greek letters, mathematical symbols, etc.) should be coded consistently throughout the text. Please
make a list of such characters and provide a key to the codes used.
Cover Letter for New Submissions
The cover letter should include the following:
o Manuscript title
o Manuscript classification (e.g., Article, Clinical / Scientific Note)
o Notification of any redundant or duplicate publication
o A statement that one author (the principal author or guarantor) takes full responsibility for the data, the analyses and
interpretation, and the con that the author has full acces and that the author has
the right to publish any and all data separate and apart from any sponsor.
o Author's statement of responsibility for clinical trial data and statement of the data results are required to be deposited
in a clinical trials database (if applicable). It is the authors’ responsibility to deposit the results into the clinical
trials database. See .
o Indication that the Methods section includes a statement that an IRB or regional review board has approved the use of
human subjects for this study
o Author's statement that permission was received from author(s) of any "personal communications" cited in the article
o Author's declaration that all authors and contributors have agreed to conditions noted on the Authorship Agreement Form
o Indication that the Author has received consent forms from any participant in a study and has them on file in case they
are requested by the editor. For a retrospective analysis that is IRB-approved, state that approval from an ethical standards
committee to conduct this study was received.
o Indication that the Author has received an authorization-for-disclosure form for any figure or video of any recognizable
participant.
Title Page
o The title should be no more than 96 characters in length, including spaces, punctuation, and subtitle. Titles should be
clinically interesting and informative. They may include widely accepted abbreviations (click
for a complete list).
o Provide a word count for the paper and abstract and a character count for the title (including spaces and punctuation).
Include number of references, tables, and figures.
o The title page should include the names of the authors followed by their highest academic degrees (MD, PhD) and their
institutional affiliations. Authors may use either full names or initials except when ther in that case,
use only initials. Include the name, address, telephone number, fax number, and e-mail address of the author who will be receiving
correspondence and proofs and the email addresses of all other authors who qualify as authors under the
o To note common first authors, mark an asterisk following each of the common authors' highest academic degree in the author
byline. Identify the asterisk at the end of the same page and state, "These authors contributed equally to the manuscript."
Note that when working through the online submission process, however, only one author can be designated as the corresponding
o The corresponding author must specify who conducted the statistical analysis with their professional affiliation (academic,
governmental, or commercial) listed.
o If applicable, authors should indicate study sponsorship or funding by listing it on the title page: Study funding: Supported
by NIH (OR ). (Funding should also be mentioned as the first item under page 2 of the Disclosure section).
o Authors should choose a maximum of 5
that cover the aspects of the submitted article. for the list of Search Terms. Please designate the term and include the number to which it corresponds.
o Page 2: The second page (and extra pages if needed) must first list all the authors and their individual contributions
to the manuscript. This information must coincide with the information on the completed by those qualifying for authorship. In addition, the second page must mention study sponsorship or funding (industry,
government, or institutional) and then disclosures of all authors' financial relationships deemed relevant to the manuscript.
Authors will be notified at the appropriate time to complete an online disclosure with all financial relationships (and those
of their immediate family members) from the past two years regardless of whether these relationships are related to the study
described in the submitted manuscript. If the study period of the submitted manuscript exceeded two years, financial relationships
for a sample disclosure statement for Page 2. Note that the disclosure must mention any corporate sponsorship of the study
first and government or institutional funding second. No dollar amounts need to be included. Authors' names, contributions,
and disclosures should appear in the same order as in the manuscript byline. Structure of sentences should be as similar as
possible to the example. The corresponding author is responsible for ensuring that author contributions and relevant disclosures
appear on the submitted, revised, and final accepted manuscripts and that the page proofs reflect the author contributions
and disclosures listed.
Disclosures of all authors that are relevant to the manuscript should appear on page 2 (or extra pages as needed) of the
manuscript. Every author should be included in the Disclosure Statement. If an author has no relevant disclosures, please
use "Dr. AUTHOR reports no disclosures." (Please note that COMPLETE disclosures must be included on the online disclosure
form and will appear online exactly as entered.) After authors complete the required forms, they should check their online
disclosures by logging into the manuscript system at
and selecting their name in the upper left-hand corner. Please note: If a paper is published, the online disclosures will
appear exactly as they do in the read-only disclosure display. Authors should review for accuracy and readability and update
their Disclosure Forms in the online tracking system as necessary.
Articles require structured abstracts that should not exceed 250 words (one double-spaced typed manuscript page). Abstracts
should b minimum statistics are sufficient. A structured abstract should be organized as follows:
o Objective
o Conclusions
o Classification of Evidence (applicable for studies of )
Papers evaluated for classification of evidence must contain the section titled Classification of Evidence after the Conclusions
section. In this section, please include the following in 25 words or less: Classification of Evidence: This study provides
Class [I, II, III, or IV] evidence that [Treatment] [reduces/increases/decreases/is well tolerated] results.
For example:
Classification of Evidence: This study provides Class I evidence that certain dosages of mexiletine are well tolerated and
effective in reducing handgrip relaxation.
This statement should be expanded to include other details in the Methods section. For Views & Reviews articles, provide
a 150- to 250-word abstract, structured if possible. NeuroImages and Clinical/Scientific Notes do not require an abstract.
Introduction
The introduction should not be more than 250 words. Be specific and concise in stating information related to the study.
Refrain from reiterating known information.
The Methods section must provide sufficient detail to allow replication of the study. As examples, the Methods should indicate
nucleotide sequences used for RNA or DNA probes, what an antibody was made against and sources of antibodies, constructs for
transgenic animals, and reagents and instruments used with the manufacturer's names and locations.
If the study reports a therapeutic intervention (clinical trial or use of medication, procedure, maneuver, or change in
patient environment intended to benefit the patient), the Methods must be sufficiently detailed to allow classification of
Papers evaluated for classification of evidence must contain a paragraph titled Classification of Evidence. In this paragraph,
please state (a) the question(s) the investigation was designed to answer, specifically identifying the patient population,
intervention of interest, a (b) the class of evidence (I, II, III, or IV) assigned to each question as
determined by ; and (c) a brief statement of the results of the study for each question. Detail dosages, percentages, years, and significance.
Classification of evidence: This interventional study provides Class I evidence that warfarin (target INR 1.7 to 2.5) is
equivalent to aspirin 81 mg daily in preventing recurrent strokes during an average of 3 years of follow-up in participants
aged 20 to 70 with a history of stroke (relative risk of stroke warfarin vs aspirin 0.98, 95% CIs 0.81 to 1.10).
Methods/Primary research question: Has the introduction of adjunctive dexamethasone in the Netherlands improved outcome
in pneumococcal meningitis? This study provides Class III evidence that dexamethasone reduced the proportion of participants
with unfavorable outcomes (Glasgow Outcome Scale score of one to four) in the
cohort, as compared to the
cohort (39 vs. 50%; odds ratio, 0.63%; 95% confidence interval, 0.46 to 0.86; p=0.002). Mortality rates (20 vs. 30%; absolute
risk difference, 10%; 95% confidence interval 4 to 17%; p=0.001) was also significantly lower in .
In a subsection on Standard Protocol Approvals, Registrations, and Patient Consents, include the following:
o A statement of approval by an ethical standards committee on human experimentation (institutional or regional) for any
experiments using human subjects.
o A statement identifying the institutional or licensing committee approving experiments performed on live vertebrates and/or
higher invertebrates.
o A statement that written informed consent was obtained from all participants (or guardians of participants) in the study
(consent for research). For a retrospective analysis that is IRB-approved, state that approval from an ethical standards committee
to conduct this study was received.
o A statement that authorization has been obtained for disclosure (consent-to-disclose) of any recognizable persons in photographs,
videos, or other information that may be published in the Journal, in derivative works by the AAN, or on the Journal's Web
site (when applicable).
o A statement, if the study reports on a clinical trial, providing the identity of the public trials registry and the clinical
trial identifier number.
To report previously published methods, provide a statement in the manuscript as follows: We used the same methodology as
the one employed in a previous study [citation]. Insert the published method verbatim immediately below, citing it appropriately.
If the verbatim wording is more than 200 words, supply permission to republish the content from the publisher of the original
See sections on Clinical Trial Guidelines, Human Subjects, Registration of Clinical Trials, Genetic Studies, Permissions
and Patient Consent, and Level of Evidence for more information.
Authors should examine a recent issue of Neurology: Neuroimmunology & Neuroinflammation to plan the appropriate layout and
size when preparing their figures.
o Neurology: Neuroimmunology & Neuroinflammation is interested in 3-D or interactive figures. If you have figures that would
be enhanced by this approach, please let the editors know and include these as part of your submission.
o Proof of permission to reprint a figure from any source is required (as is permission to modify a figure, if applicable);
figures previously published anywhere will not be published in Neurology: Neuroimmunology & Neuroinflammation without documented
permission from the copyright holder.
o Color figures are published with no charge to authors. o Use Arial type within figures, capitalizing the first letters
of first words of labels only. Ensure that the spacing between letters (kerning) is even (no letters closer together than
the others) and that the lettering is crisp.
o Per Journal style, each figure has a short title above it (the detailed legend is placed under the figure). Provide a
short title (15 words or less) for each figure at the beginning of the Figure Legend in the manuscript file.
o Title and Figure legends should be double-spaced and appear on a separate page of the manuscript document file.
o Footnotes should be noted as superscript a, b, c, etc.
o Multipart figures should be labeled with capital letters A, B, C, (using Arial font) etc. in the upper left-hand corner
of each panel. Please submit multipart figures as composite files. Panels should read from left to right, then down.
o In graphs, standard symbols should be used for data points in the following order: Symbols like the following are not
acceptable: To prevent wasted space, axes should end no more than one increment beyond the final data points. Explanatory
lettering should not extend beyond the ends of the axes.
o Remove extraneous lines from graphs (only include x, y axis).
o Line graphs should be solid colored lines rather than dots and dashes.
o Bar fill in bar graphs should be solid color rather than patterns. o Figures should not include titles or patient initials.
Titles should be placed in the figure legend, not on the figure itself. Abbreviation keys should be placed in the figure legend
unless they fit into the confines of the figure.
o Internal scale markers must appear on microscopic photographs.
o Remove white type from MRIs, CTs, etc.
o Number figures (including figures to be published online only) in the order of their mention in the text.
o For supported electronic file requirements, see the section on Electronic Figure, Video, Supplemental Data Submission.
Tables should be created using a structured table format in Word and included as part of the manuscript document file. Do
not embed image files of tables and do not use tabs in creating tables. Authors should consult a recent issue of Neurology:
Neuroimmunology & Neuroinflammation before designing tables.
o Tables should be brief and easily understood without referring to the text.
o Do not use color or shading within tables.
o Do not include patient names or initials in the tables.
o Place each table, including a title and legend (if applicable), on a separate page.
o All tables must be double-spaced.
o Number tables in the order of their mention in the text.
o References cited within a table should use numbers rather than author names.
o Tables should be no longer than two double-spaced manuscript pages.
Supplemental Data
Neurology: Neuroimmunology & Neuroinflammation does not allow supplementary data to be published with the accepted article
except for Video and Coinvestigator appendicies. In this area, please also enter any articles that are in press that are related
to the submitted manuscript. The data must be in a separate electronic file rather than included in the main document.
If the manuscript is accepted, this supplemental data will be posted as submitted and will not be professionally copyedited
or proofread. For this reason, authors should carefully review their material. Neurology: Neuroimmunology & Neuroinflammation
will not be responsible for errors or omissions. See Supplemental Data/Additional Files for upload information.
Reference Style
o Cite references in numerical order according to their position in the Reference list in the text.
o List all authors when th for seven or more, list only the first three and add "et al."
o Use PubMed abbreviations for journal names but eliminate U.S. cities cited in parentheses after the name of a journal.
o Use continuous pagination (e.g., 33-37, not 33-7). o Do not reference papers that are "submitted"; unpublished papers
must be accepted and in press.
o Authors must provide "submitted" and "in press" manuscripts clearly labeled as such by uploading them as supplemental
files with submission or faxing them to the editorial office.
o Personal communications should be mentioned in the body of the manuscript (not in the references). The author must state
in writing in the cover letter of the submission that permission was obtained by the author of any personal communication
cited in the article.
Neurology: Neuroimmunology & Neuroinflammation reference style is similar to the style described in the Uniform Requirements
for Manuscripts Submitted to Biomedical Journals (), with the exception that pagination should be complete. The following are sample styles for submission. See the Uniform
Requirements for guidance on other reference types. The following are sample styles for submission:
o Journal article Zangerle A, Kiechl S, Spiegel M, et al. Recanalization after thrombolysis in stroke patients: predictors
and prognostic implications. Neurology -44.
o Journal article published electronically ahead of print version Shi J, Zhao C, Vollmer TL, Tyry TM, Kuniyoshi SM. APOE
e4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology Epub 2007 Apr 25.
o AAN Annual Meeting abstract published in print (before 2012) Rocca W, Grossardt B, Ahlskog E, Bower J, De Andrade M, Maraganore
D. The Mayo Clinic Cohort Study of Oophorectomy and Aging: results for dementia and cognitive impairment. Neurology 2006;66(suppl
2):A216. Abstract.
o AAN Annual Meeting abstract published online (2012 and after) Cheung T, Flatow V, Ben-Haim S, et al. Status dystonicus
following deep brain stimulation surgery in DYT1 dystonia patients. Neurology 2012;78: P01.227.
o Conference paper Mark MH, Dickson DW, Schwarz KO, et al. Familial diffuse Lewy body disease. Presented at the 10th International
Symposium on Parkinson's D October 19, 1991; Tokyo.
o In press (forthcoming) Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis.
Proc Natl Acad Sci USA (in press 2002).
o Letter Gotkine, M. Vascular risk factors and cognitive decline among elderly male twins. Neurology 1. Letter.
o Online letter Henderson VW, Drachman DA. Dementia and voter competence [electronic response to Swerdloff, Post-election
anecdote]. Neurology 2002. http://www.neurology.org/cgi/eletters/58/7/995 (accessed 21 May 2002).
o Book Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical Microbiology, 4th ed. St Louis: M 2002.
Gilstrap LC 3rd, Cunningham FG, VanDorsten JP, editors. Operative Obstetrics, 2nd ed. New York: McGraw-H 2002.
Meltzer PS, Kallioniemi A, Trent JM. Chromosome Alterations in Human Solid Tumors. In: Vogelstein B, Kinzler KW, editors.
The Genetic Basis of Human Cancer. New York: McGraw-H .
o Online book or Web site Garrow A, Weinhouse G. Anoxic brain injury: assessment and prognosis. In: UpToDate Cardiovascular
Medicine [online]. Available at: . Accessed February 22, 2000.
o Online journal article Miyamoto O, Auer RN. Hypoxia, hyperoxia, ischemia, and brain necrosis. Neurology [serial online]
-371. Available at: www.neurology.org. Accessed February 23, 2000.
o Monograph in electronic format Chee M, Chiappa K. Waveguide: an EEG atlas on CD-ROM. Philadelphia: Lippincott Williams
& Wilkins, 1998.
Appendices
o Provide information that is explanatory or statistical in nature in an Appendix.
o If the Author list is longer than the space in the Author byline area of the first page of the published paper, the Authors
whose names do not fit will be listed in an Appendix. This list includes Coinvestigators in multi-center trials attributed
to corporate or multiple Authors if the investigators qualify as Authors according to one of the criteria under .
o Coinvestigators and Study Coordinators for multi-center trials who do not qualify as Authors according to one of the criteria
under Authorship Definition must be listed in a data supplement titled "Coinvestigators." Coinvestigators will be indexed
by PubMed.
o Disclosures for authors will be contained in an appendix called Disclosures at the end of the published article if these
disclosures take more space than available in the disclosure section on the first page of the article.
Acknowledgment
The Acknowledgment section allows authors space to recognize and express appreciation to others () who have contributed to the study but have not qualified as Authors or Coinvestigators. In this section, list those who
contributed drugs, reagents, equipment,
o or edited the manuscript for non-intellectual content. The list must include the contributors' affiliations
and the specific contributions made by each. The Acknowledgment section is also reserved for authors to thank individuals
who have provided general advice or guidance, review of the manuscript, and technical help. For those helping in preparation
of the manuscript, please specify how they assisted (e.g., performed substantive or technical editing, copyedited the manuscript,
prepared tables or figures, or provided clerical assistance).
Online Manuscript Submission
http://submit.nn.neurology.org
Registering with Bench&Press
The journal’s online submission and manuscript tracking system is Bench&Press, located at http://submit.nn.neurology.org.
At the Bench&Press home page, enter the author area and click on the "Submit a new manuscript" hyperlink to begin a manuscript
submission. Users must register when accessing the Bench&Press system for the first time. A password will be created that
applies to all journals using the system. Once you have registered for your first Bench&Press journal, you do not need to
re-register in order to use another journal's system. Simply log on with your existing email address and password.
To set up your personal Bench&Press access, click on "Create a new account." You will be asked to complete three steps:
o E-mail/password. Enter your e-mail address. This is your unique user identification and will be needed to log onto the
system on all occasions (as a reviewer or author). Enter a password. This will be encrypted for security reasons, and will
not be known to Neurology: Neuroimmunology & Neuroinflammation or Bench&Press staff.
o Verification. A verification e-mail containing a URL will be e-mailed to you at the address you used to register. You
will need to click on the URL provided in the e-mail or copy and paste it into the address field in your Web browser. This
will verify your e-mail address and help to ensure that your e-mail address is not being used fraudulently.
o Prof